Investigating ZNF410 to increase fetal hemoglobin levels
Official title: Targeting ZNF410 for HbF reactivation
Funded at Boston Children's Hospital · NIH-11051852 · Data updated 2026-11-12
This study is looking at a protein called ZNF410 to see if it can help boost fetal hemoglobin levels in people with sickle cell disease and β-thalassemia, with the hope of finding new treatments that make living with these conditions easier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $605,162 |
| NIH project number | 5R01HL167513-03 |
| Project ID | NIH-11051852 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with sickle cell disease or β-thalassemia who are 21 years or older.
✕Less likely to help
Patients with hemoglobin disorders who are under 21 years old may not benefit from this research.
What this research studies
This research focuses on understanding how ZNF410, a protein that regulates fetal hemoglobin (HbF), can be targeted to increase HbF levels in patients with hemoglobin disorders like sickle cell disease and β-thalassemia. By exploring the mechanisms of ZNF410's action and its role in blood cell formation, the research aims to develop new pharmacotherapies that could effectively treat these conditions. The approach includes studying the interactions of ZNF410 with other proteins and testing targeted therapies that could enhance HbF production, potentially offering a new treatment avenue for patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the management of hemoglobin disorders, reducing reliance on supportive therapies.
How similar studies have gone: Other research has shown promise in targeting similar pathways for increasing fetal hemoglobin, suggesting that this approach could be effective.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Bauer, Daniel Evan — Boston Children's Hospital
- Study coordinator: Bauer, Daniel Evan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.